Inhibition of phosphatidic acid phosphohydrolase activity by sphingosine Dual action of sphingosine in diacylglycerol signal termination by Lavie, Yaakov et al.
Volume 277, number 1,2, 7-10 FEW 09221 December 1990 
Inhibition of ~hus~hatidiG acid ~hos~h~hydrolas~ ctivity by s~hi~~osin~ 
Dual action of sphin~os~ne in diacylglycerol signal te~inatio~ 
Yaakov Lavie, Orly Piterman and Mordechai Liscovitch 
~e~artrnen~ ~~~~rrn~ne ~e~~ear~h, The Weizma~~ institute of Science. ~e~~vot ~~i~~ Israel 
Received 17 October 1990 
Recent evidence indicates that a major fraction of diacylgIyceroi that is produced in hormonally stimulated cells arises by phosphatidyfcholine 
hydrolysis via the sequential action of phospholi~a~ D and phosphatidic acid phosphohydrolase (PAP). We have previously reported that 
sphmgoid bases stimulate phospholipase D activity in NGIOS-I5 cells. The evidence presented here demonstrates that in sphingosine-treated 
NG 108-I 5 cells, elevated phosphatidic acid levels are accompanied by a parallel, time- and dose-de~ndent decrease in diacyl~ly~rol levels. DL- 
propranoiol, a known inhibitor of PAP, exerted similar effects, suggesting that the action of sphingosine may have been due to inhibition of PAP 
activity. This prediction was confirmed in in vitro experiments in which it was demonstrated that sphingosine is as potent an inhibitor of both 
cytosolic and membrane-associated PAP activity as propranolol. The hypothesis that sphingoid bases may exert a dual action in diacylglycerol 
signal termination is proposed. 
Sphingoid base; Signal transduction; NGI08- I5 cell 
I, INTRODUCTION 2. EXP~Rl~ENTAL 
Long-chain amino (sphingoid) bases form the 
backbone of sphingolipids, important membrane con- 
stituents which are particularly concentrated in brain 
and nerve tissue [I]. Over the past 3 years, sphingoid 
bases emerged as a new class of putative, physiologic 
bio-regulatory molecules, primarily because they inhibit 
the activity of the Ca”/phospholipid-dependent en- 
zyme protein kinase C (PKC) in vitro and of various 
cellular events which depend on its activation [2,3]. In- 
triguingly, 1,2-sn-diacylglycerol, the second messenger 
activator of PKC, can stimulate sphingomyelinase ac- 
tivity in GH, pituitary cells and elevate free sphingosine 
levels 141; moremover, the action of sphingomyelinase 
can reverse PKC activation [5,6]. Hence, it was 
hypothesized that free sphingosine may funcion as an 
endogenous, negative modulator of PKC f2-61. In a 
previous study we demonstrated that sphingosi~e 
stimulates cellular phosphoiipase D activity and causes 
a marked increase in phosphatidic acid levels 171. We 
now report that sphingosine also inhibits the activity of 
phosphatidic acid phosphohydrolase (PAP), an enzyme 
that hydrolyses phosphatidic acid to produce diacyl- 
glycerol (81. 
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Ievels in intact cells 
NClOS-15 cells were routinely cultured as previously described [9]. 
To metabolically label phospholipids, 4 x 104 cells (grown in a 75cm’ 
flask) were preincubated for 24 h with SO&i of [3H]ofeic acid (or 10 
pCi of [3H]arachidonic acid, as in Fig. 21, in Dulbecco’s Modified 
Eagle’s M~i~rn that contained 0.1% fatty acid-free bovine serum 
albumin (DMEM/BSA). The cells were then rinsed once, detached, 
suspended in DMEM/BSA and allowed to recover for 3 h at 37°C 
before experiments began. Ceils (2 x 10’ cells in 1 ml of DMEM/BSA) 
were incubated in 12x75-mm glass tubes at 37°C with 50 pM 
sphingosine for the indicated time. Incubations were terminated by 
adding 1 ml of ice-cold acidified methanol and vortexing. Lipids were 
extracted from the cells essentially as described [IO]. Phosphatidic 
acid was separated from other lipids by double-development thin 
layer chromatography (TLC) on 10 x ZO-cm sihca gel 60 plates accor- 
ding to Bocckino et al. [l l]. Bands corresponding to phosphatidic 
acid carrier are scraped off and quantitated by liquid scintillation 
spectrometry. [3~]DiacylglyceroI was quantitated by TLC on Silica 
Gel 60 aluminum sheets using benzene/ethyl acetate (7:3) as the 
mobile phase. 
22. Assay of phQ~~har~d~~ acid ~ho~~hohydr~~a~e activity in 
s~bcefl~iar fractions 
Subcellular fractions were prepared from NGIOS-15 cells. Cells 
were suspended at 4% in 10 mM Tris-HCl, pH 7.4, containing 1 mM 
dithiothreitol. The cells were sonicated with a probe sonicator (Heat 
System Ultrasonics), 10 pulses of 5 s cycles at 4°C. The homogenate 
was centrifuged for 10 min at 18OOOxg at 4°C. The resufting super- 
natant was then centrifuged for 80 min at 105OOOxg, to produce a 
microsomal pellet and a supernatant fraction. The pellet was then 
resuspended in 10 mM Tris-HCI, pH 7.4, containing 1 mM 
dithiothreitol and both fractions were stored at - 70°C until used. 
~3H]Phosphat~dic a id was prepared from total NGIOS-15 cells; 
phospholipids, metabolically labeled with [3H]oleic acid, by incuba- 
tion with cabbage phospholipase D, essentiatly according to Eibl and 
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Fig. 1. Reciprocal and concurrent effects of sphingosine on levels of 
~3H]phosphatidic acid (solid circles) and [3H]diacylglycerol (open 
circles). [‘H]Phosphatidic acid and [3H]diacylglycerol were determin- 
ed as detailed in section 2. Results are expressed as the mean k SE of 
two independent experiments, each performed in duplicate. 
Kovatchev 1121. [3H]Phosphatidic acid was purified by TLC on Silica 
Gel 60 plates using the upper phase of a mixture of ethyl acetate 
/isooctane/acetic acid/water (1.10: 5O:ZO: 100) and was 90% pure by 
Z-dimensional TLC analysis. The specific radioactivity of the purified 
[‘Hlphosphatidic acid was 25 Ci/mol. Phosphatidic acid phospho- 
hydrolase activity was assayed by measuring the production of 
13H] I ,2-diacylglycerol, essentially according to Martin et al. [ 131. The 
incubation mixture, in a final volume of 0.1 ml, contained 100 mM 
Tris-HCI, pH 7.4, 1 mM dithiothreitol, 2 mgfml BSA (essentially fat- 
ty acid-free), 2 mM MgC12, 1 mM EGTA, 1 mM EDTA, 0.6 mM 
phosphatidic acid (Sigma), [3H]phosphatidic acid (5 x IO’ cpm), 0.4 
mM I-palmitoyl-2-oleoyl-phosphatidylcholine (Avanti) and 50 pg of 
cytosol or microsomal protein. To prepare the mixed phospholipid 
vesicles which served as substrate, appropriate amounts of the lipids 
were dried under a stream of nitrogen and sonicated in 4 mM 
EGTAI4 mM EDTA mixture with a probe sonicator for 1 min. The 
reaction was carried out at 37’C for 30 mm and was terminated by the 
addition of 1 ml methanol/O.1 N HCl(150: I), 1 ml chloroform and 
1 ml aqueous EGTA 1 mM. The chloroform phase was collected, 
dried and [3H]diacylglycerol was separated and counted as described 
in section 2.1. 
3. RESULTS AND DISCUSSION 
Neuroblastoma x glioma hybrid NGl08-15 cells 
were pre-labeled with [3H]oleic acid and the formation 
of [3H]diacylglycerol and [3H]phosphatidic acid, after 
treatment with sphingosine, was monitored. As shown 
in Fig. 1, sphingosine elicits a half-maximal reduction 
in 13H]DAG levels within 4 min of incubation and a 
maximal reduction within 15 min. The reduction in 
[3H]diacylglycerol levels slightly precedes the elevation 
in [3H]phosphatidic acid levels, which reaches half- 
maximal levels within 10 min and maximal evels within 
30 min. The dependence of diacylglycerol and phos- 
phatidic acid levels on sphingosine concentrations was 
examined in both [3H]oleic acid-labeled and [3H]ara- 
chidonic acid-labeled cells, and compared to the effects 
of the known PAP inhibitor DL-propranolol 114,151. 
Fig. 2 shows that the effect of sphingosine on t3H]dia- 
cylglycerol and [3H]phosphatidic acid levels was dose- 
dependent. During 30 min of incubation, sphingosine 
induced half a maximal decrease of [arachido- 
noyl-3H]diacylglycerol and [oleoyl-3H]diacylglycerol at 
concentrations of 24 pM and 9 FM, respectively. Con- 
comitantly, sphingosine induced a half-maximal accu- 
mulation of [arachidonoyl-3H]phosphatidic acid and 
[oleoyl-3H]PA at concentrations of 20 PM and 10 PM, 
respectively. Thus, with both [3H]fatty acid labels, the 
concentration of sphingosine required for stimulating 
phosphatidic acid accumulation is similar to the con- 
centration required for reducing diacylglycerol levels. 
The sphingosine concentration-response curves resem- 
ble those of propranolol (Fig. 2). The 50% effect con- 
centrations of propranolol-induced changes in 
[3H]diacylglycerol and ~3H]phosphatidic acid were 27 
PM and 46 ,uM, respectively, in [3H]arachidonic acid- 
labeled cells, and 18 PM and 37 PM in [3H]oleic acid- 
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Fig. 2. Dose-dependent effects of sphingosine and propranolol on 
levels of [‘HJphosphatidic acid (solid circles) and [‘H]diacylglycerol 
(open circles). Cells were pre-labeled either with [3H]arachidonic acid 
(A,B) or with [‘H]oleic acid (C,D), and incubated with the indicated 
concentrations of sphingosine (A,C) or propranolol (B,D) for 30 min. 
[3H]Phosphatidic acid and [3H]diacylglycerol were determined as 
detailed in section 2. Results are expressed as the mean i SE of two 
(A,B,D) or three (C) independent experiments, each performed in 
duplicate. 
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Fig. 3. Effects of sphingosine (open circles) and propranolol (solid 
circles) on phosphatidic acid phosphohydrolase activity in vitro. (A) 
Cytosolic PAP. (B) Membrane-associated PAP. Results are expressed 
as the mean of duplicate determinations from a representative experi- 
ment, repeated twice. 
labeled cells. The decrease in [3H]phosphatidic acid ac- 
cumulation evident at high concentrations of sphingo- 
sine, but not of propranolol, is most likely due to the 
known cytotoxic effect of this compound [16]. Apart 
from that, there was a close correlation between the ef- 
ficacy of these two compounds. 
The similarity between the effects elicited by 
sphingosine and those of propranolol suggested that 
sphingosine too may act as an inhibitor of PAP activity. 
To evaluate this possibility we examined the direct ef- 
fect of sphingosine on PAP activities present in cytosol 
and microsomes prepared from NG108-15 cells (Fig. 3). 
Enzyme activity was measured in vitro by the produc- 
tion of [3H]diacylglycerol from mixed liposomes con- 
taining [3H]phosphatidic acid and phosphatidylcholine. 
The properties of NG108-15 cytosolic and microsomal 
PAP activities resemble those of the equivalent liver ac- 
tivities (0. Piterman and M. Liscovitch, in prepara- 
tion). Sphingosine inhibited both the cytosolic and the 
membrane-associated PAP activities, exhibiting I&, 
values of 240 and 250 PM, respectively (Fig. 3). Pro- 
pranolol inhibited PAP activity with I&, values that 
were somewhat higher than those of sphingosine (380 
PM and 330 PM, for the cytosolic and the membrane- 
associated enzyme, respectively). It was therefore con- 
cluded that sphingosine is capable of inhibiting PAP ac- 
tivity in NG108-15 cells. The mechanism of PAP inhibi- 
tion by sphingosine is presently unknown. The 
mechanism of PAP inhibition by propranolol is believ- 
ed to involve its direct interaction with the negatively 
charged phosphatidic acid [14,15]. Propranolol can be 
categorized as a cationic amphiphilic drug [ 171, a class 
of compounds with which sphingosine shares important 
structural features, i.e. the positively charged amino 
group and a hydrophobic domain. Sphingosine may 
therefore be categorized as a natural cationic am- 
phiphilic molecule, and its mechanism of PAP inhibi- 
tion may be similar to that of other cationic amphiphilic 
drugs. 
Accumulating evidence indicates that a major frac- 
tion of diacylglycerol that forms in signal-activated cells 
is generated from phosphatidylcholine, by the sequen- 
tial action of phospholipase D and PAP (Fig. 4) 
[18,19]. Therefore, the present results suggest hat, by 
virtue of its inhibitory effect on PAP activity, sphin- 
gosine may decrease the availability of diacylglycerol 
and thus may negatively modulate the activity of PKC. 
Moreover, a recent study has demonstrated that sphin- 
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Fig. 4. A schematic and semi-hypothetic diagram of signal-induced 
generation of diacylglycerol and phosphatidic acid and their inter- 
conversion, and negative feedback regulation by sphingosine of 
diacylglycerol-dependent signalling. Solid arrows indicate metabolic 
reactions while thick, shaded arrows represent either stimulatory 
(plus) or inhibitory (minus) regulatory effects. DAG is depicted as be- 
ing produced from PC by the sequential action of phospholipase D 
(reaction 1) and PAP (reaction 2). Recent studies indicate that this in- 
direct pathway is quantitatively the most important source of DAG 
generated in stimulated cells [l&19]. DAG activates PKC, 
simultaneously and independently stimulating the activity of a neutral 
sphingomyelinase [6] (reaction 4). This leads (after the action of 
ceramidase, reaction 5) to production of free sphingosine. 
Sphingosine has a direct inhibitory effect on PKC activity [21]. Con- 
currently, sphingosine blocks the generation of DAG by inhibiting 
PAP activity (present report) and enhances DAG removal by 
stimulating an 80 kDa diacylglycerol kinase isozyme [20] (reaction 3). 
This results in decreased DAG levels, inactivation of PKC (accom- 
panied by its translocation back to the cytosol [5]) and hence, signal 
termination. Thus, sphingosine exert a dual - direct and indirect - in- 
hibitory action on DAG and PKC signalling. The reciprocal regula- 
tion of PAP and diacylglycerol kinase by sphingosine, as well as the 
activation of phospholipase D [7,22] leads to an increase in PA levels. 
For the sake of simplicity, the possible role of PA as an intracellular 
messenger in its own right (cf. [I8 and 191) is not depicted in this 
scheme. See text for a more detailed discussion. Abbreviufions: DAG, 
diacylglycerol; PA, phosphatidic acid; PC, phosphatidylcholine; SM, 
sphingomyelin; PKC, protein kinase C. 
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gosine markedly activates an 80-kDa diacylglycerol 
kinase isozyme [ZO]. This suggests that sphingosine may 
inhibit the generation of diacylglycerol by PAP while 
concomitantly stimulating diacylglycerol metabolism. 
The two enzymes that catalyze the inter-conversion of 
diacylglycerol and phosphatidic acid - PAP and diacyl- 
glycerol kinase - may thus be coordinately and reci- 
procally modulated by sphingosine. Hence, in addition 
to its direct, inhibitory effect on PKC, which involves 
interference with the binding of PKC to the ternary 
complex formed at the plasma membrane by Ca2+, 
phosphatidylserine and the signal-generated DAG [21], 
sphingosine may also terminate PKC activity by 
decreasing the amount of diacylglycerol available for its 
activation. 
Our hypothesis that sphingosine inhibits diacyl- 
glycerol generation complements and completes a 
model put forth by Kalesnick [5,6] for the termination 
of PKC activation by endogenous phingosine (Fig. 4). 
According to this model, diacylglycerol activates a 
membrane Sph~ngomyeIinase, giving rise (following the 
action of a ceramidase) to free sphingosine. We here 
propose that the endogenous sphingosine thus gen- 
erated may now decrease diacylglycerol production (by 
inhibiting the activity of PAP) and stimulate its 
metabolism (by activation of diacylglycerol kinase), 
thus completing a self-contained negative feedback 
loop. Whether the inhibitory effect of sphingosine on 
PAP activity reflects a physiological control pathway 
and the postulated dual role of sphingoid bases in 
diacylglyceroi signal termination remain to be establish- 
ed by future research. 
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